Exclusive: After Survey Flags 2,800% Pharma Profit, Tukaram Mundhe Calls For Transparency

There is a 2800 per cent profit in the price of an IV set at which manufacturers sell to hospitals and the Maximum Retail Price and that indicates a need for a relook into the pricing and profit issues, Maharashtra FDA Commissioner Tukaram Mundhe told NDTV in an exclusive interview today. Following a market survey by the Maharashtra State Price Monitoring Resource Unit under the state FDA to assess pricing patterns of medical devices sold in retail and trade markets, Mundhe has written to the National Pharma Pricing Authority under the Department of Pharmaceuticals, asking for intervention.While pharma or any other industry will not work to incur losses, he said there needs to be transparency.